Celldex Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Cantor Fitzgerald Cuts Price Target on Celldex (CLDX) to $31 Following Rintega Filing Delay
August 11, 2015 10:10 AM EDTCantor Fitzgerald maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $38.00), following its decision to delay BLA filing for Rintega. Analyst Mara Goldstein said that filing for Rintega is not likely until the completion of ACT IV. ACT IV is expected... More
Brean Capital Cuts Price Target on Celldex (CLDX) Following Talks with FDA
August 11, 2015 7:07 AM EDTBrean Capital maintained a Buy rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $31.00 (from $35.00), following company talks with the FDA. CLDX has received enough feedback to conclude that it will not file Rintega for Accelerated Approval in recurrent GBM.
Analyst... More
Cowen Cuts Price Target on Celldex (CLDX) Following 2Q and Clinical Update
August 11, 2015 6:58 AM EDTCowen maintained an Outperform rating on Celldex Therapeutics (NASDAQ: CLDX), and cut the price target to $28.00 (from $34.00), following 2Q earnings and clinical update. CLDX has decided not to file for acceleration of Rintega. Analyst Boris Peaker is disappointed by the rindo filing... More
Celldex (CLDX) Reports Q2 Loss of $0.33
August 10, 2015 4:51 PM EDTCelldex (NASDAQ: CLDX) reported Q2 EPS of ($0.33), versus ($0.32) reported last year. Revenue for the quarter came in at $2.2 million, versus $592 thousand reported last year.
For earnings history and earnings-related data on Celldex (CLDX) click here.
... More